Evidence map›Paper›PMID 40016709›Full record

ArticleBMC pediatrics2025

A long-term survivor of congenital KMT2A-R B-lymphoblastic leukemia with persistently positive bone marrow MRD and multiple CNS relapses.

Taxiarhia J Arabatzis, Biren Desai, Sandra Baril, Susan Rasul, Girmay Tekle-Yohannes, Michal Ann Miller

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Taxiarhia J ArabatzisDepartment of Internal Medicine-Pediatrics, Janet Weis Children's Hospital, Danville, PA, USA.
Biren DesaiDepartment of Internal Medicine-Pediatrics, Janet Weis Children's Hospital, Danville, PA, USA.
Sandra BarilDepartment of Pediatrics, Janet Weis Children's Hospital, Danville, PA, USA.
Susan RasulDepartment of Internal Medicine-Pediatrics, Janet Weis Children's Hospital, Danville, PA, USA.
Girmay Tekle-YohannesDepartment of Pediatric Hematology and Oncology, Janet Weis Children's Hospital, 100 N Academy Ave, Danville, PA, 17822, USA.
Michal Ann MillerDepartment of Pediatric Hematology and Oncology, Janet Weis Children's Hospital, 100 N Academy Ave, Danville, PA, 17822, USA. mamiller2@geisinger.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we describe the case of an infant incidentally diagnosed with congenital KMT2A-rearranged (KMT2A-r) B-cell ALL on Day of Life 4. He received the first dose of intrathecal methotrexate on DOL 5, and induction systemic therapy on DOL 6. He demonstrated morphologic remission at the end of induction but had positive bone marrow. Minimal residual disease (MRD) was 1.4%. He experienced isolated CNS disease after consolidation and immunotherapy. At 8 months of age he underwent hematopoietic stem cell transplantation (HSCT). At 14 months of age he had medullary and CNS relapse, and at 16 months of age underwent CD19 CAR-T therapy. At 6 years of age he remains in remission with tolerable developmental delays and a good quality of life.

Indexed as

Central Nervous System NeoplasmsHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBone MarrowHematopoietic Stem Cell TransplantationHumansInfantInfant, NewbornMaleNeoplasm, ResidualRecurrenceSurvivorsHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinB-cell acute lymphoblastic leukemiaCD 19 CAR T-cell therapyKMT2A–rNeonatology

Identifiers

PMID40016709
PMCPMC11869613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.